AI pathology → androgen deprivation duration

This diagnostic-therapeutic pairing links Digital pathology & AI to the choice of Androgen deprivation & AR pathway inhibitors in Prostate cancer: an AI reading of the biopsy slide says whether adding hormone therapy to radiation will help. The rationale is that tissue morphology encodes biology beyond the Gleason grade, and because the model was trained on randomised trial cohorts its prediction is causal for treatment effect. ArteraAI Prostate, authorised by the FDA through the de novo pathway in 2025, predicts benefit from short-term androgen deprivation in intermediate-risk disease using slides from RTOG trials, and it is listed by the NCCN. The pairing is reached from the Prostate cancer, Digital pathology & AI and Androgen deprivation entries.